Michele Ardolino
Overview
Explore the profile of Michele Ardolino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
2020
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bastin D, Kilgour M, Shorr R, Sabri E, Delluc A, Ardolino M, et al.
Cytotherapy
. 2024 Dec;
27(3):350-364.
PMID: 39692673
Background: Chimeric antigen receptor (CAR) engineered NK cells (CAR-NK) are a novel approach to the immunotherapy of hematologic malignancies which seeks to overcome some of the challenges faced by CAR-T...
2.
St-Denis-Bissonnette F, Qiu S, Cummings S, Kirkby M, Haile Y, Wassmer S, et al.
J Extracell Biol
. 2024 Jul;
3(7):e166.
PMID: 39022723
Natural killer cell-derived extracellular vesicles (NK-EVs) are candidate biotherapeutics against various cancers. However, standardised potency assays are necessary for a reliable assessment of NK-EVs' cytotoxicity. This study aims to thoroughly...
3.
Hodgins J, Abou-Hamad J, ODwyer C, Hagerman A, Yakubovich E, de Souza C, et al.
J Exp Med
. 2024 Jun;
221(7).
PMID: 38869480
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells....
4.
Mediratta K, El-Sahli S, Marotel M, Awan M, Kirkby M, Salkini A, et al.
Front Immunol
. 2024 Apr;
15:1366197.
PMID: 38601156
Introduction: Chemotherapy remains the mainstay treatment for triple-negative breast cancer (TNBC) due to the lack of specific targets. Given a modest response of immune checkpoint inhibitors in TNBC patients, improving...
5.
Bergin C, Zouggar A, Mendes da Silva A, Fenouil T, Haebe J, Masibag A, et al.
Nat Cancer
. 2024 Feb;
5(3):463-480.
PMID: 38351181
Cancer stem cells (CSCs), functionally characterized by self-renewal and tumor-initiating activity, contribute to decreased tumor immunogenicity, while fostering tumor growth and metastasis. Targeting G9a histone methyltransferase (HMTase) effectively blocks CSC...
6.
Abou-Hamad J, Hodgins J, Yakubovich E, Vanderhyden B, Ardolino M, Sabourin L
Cells
. 2024 Jan;
13(1).
PMID: 38201278
Targeted therapy resistance frequently develops in melanoma due to intratumor heterogeneity and epigenetic reprogramming. This also typically induces cross-resistance to immunotherapies. Whether this includes additional modes of therapy has not...
7.
Galpin K, Rodriguez G, Maranda V, Cook D, MacDonald E, Murshed H, et al.
Sci Rep
. 2024 Jan;
14(1):787.
PMID: 38191799
The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg...
8.
Azad T, Rezaei R, Singaravelu R, Pelin A, Boulton S, Petryk J, et al.
Nat Commun
. 2023 May;
14(1):3035.
PMID: 37236967
The large coding potential of vaccinia virus (VV) vectors is a defining feature. However, limited regulatory switches are available to control viral replication as well as timing and dosing of...
9.
Kilgour M, Bastin D, Lee S, Ardolino M, McComb S, Visram A
Front Immunol
. 2023 May;
14:1166038.
PMID: 37205115
Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have revolutionized treatment for several cancer types over the past decade. Despite this success, obstacles including the high price tag, manufacturing...
10.
Abou-Hamad J, Hodgins J, de Souza C, Garland B, Labreche C, Marotel M, et al.
iScience
. 2022 Nov;
25(12):105524.
PMID: 36437876
SOX10 is a key regulator of melanoma progression and promotes a melanocytic/differentiated state. Here we identified melanoma cell lines lacking SOX10 expression which retain their growth capabilities. More importantly, we...